Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-800CW for endometriosis detection
NCT02975219Phase 1Unknown
- Sponsor
- University Medical Center Groningen
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab-IRDye800CW in endometriosis, sponsored by University Medical Center Groningen. Primary endpoint: Tracer accumulation of bevacizumab-800cw in endometriosis lesions. Status: unknown.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT02975219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975219.